Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lurbinectedin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Immedica Pharma AB

            Deal Size: Undisclosed Upfront Cash: $2.1 million

            Deal Type: Agreement April 29, 2020


            Immedica gets an exclusive distribution and marketing right of the anti-tumor drug lurbinectedin for territories that include the UK, Ireland, the Nordic countries, Middle East and North Africa.